MapLight Therapeutics 公布精神分裂症药物 Ml-007C-Ma 二期 Zephyr 试验积极顶线结果

美股速递
Jul 27

MapLight Therapeutics 宣布,其针对精神分裂症的在研药物 Ml-007C-Ma,在二期 Zephyr 临床试验中取得了积极的顶线结果。这一里程碑式的进展,为饱受精神分裂症困扰的患者群体带来了新的希望。该研究的详细数据,将在后续的医学会议上进一步公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10